{
    "nctId": "NCT00691912",
    "briefTitle": "Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin",
    "officialTitle": "Extended Dose Frequency 1st-line Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (Myocet\u00ae)",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "progression free survival assessed by imaging procedures",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\>/= 18 years with histologically proven metastatic breast cancer\n* No prior chemotherapy in the advanced situation\n* ECOG \\</= 2\n* Adequate bone marrow reserve\n* left ventricular ejection fraction (LVEF) \\>/= 50, measured within 4 weeks before study treatment\n* Existence of written informed consent\n\nExclusion Criteria:\n\n* Previous high dose therapy with stem cell support\n* Prior adjuvant treatment with cumulative anthracycline dose of 600 mg/m\u00b2 Epirubicin, 300 mg/m\u00b2 Doxorubicin, 80 mg/m\u00b2 Mitoxantrone\n* Concomitant hormon- or chemotherapy or radiation therapy\n* Her2/neu overexpression\n* pregnancy or breast feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}